Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Exagen (XGN) over the last 7 years, with Q3 2025 value amounting to 0.26%.

  • Exagen's Return on Capital Employed rose 1500.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 0.37% for FY2024, which is 200.0% up from last year.
  • As of Q3 2025, Exagen's Return on Capital Employed stood at 0.26%, which was up 1500.0% from 0.36% recorded in Q2 2025.
  • In the past 5 years, Exagen's Return on Capital Employed ranged from a high of 0.14% in Q2 2021 and a low of 0.61% during Q3 2023
  • For the 5-year period, Exagen's Return on Capital Employed averaged around 0.38%, with its median value being 0.4% (2024).
  • Per our database at Business Quant, Exagen's Return on Capital Employed plummeted by -3500bps in 2023 and then skyrocketed by 2100bps in 2024.
  • Quarter analysis of 5 years shows Exagen's Return on Capital Employed stood at 0.21% in 2021, then tumbled by -164bps to 0.55% in 2022, then rose by 11bps to 0.49% in 2023, then grew by 8bps to 0.45% in 2024, then skyrocketed by 41bps to 0.26% in 2025.
  • Its Return on Capital Employed was 0.26% in Q3 2025, compared to 0.36% in Q2 2025 and 0.49% in Q1 2025.